Updates on Aspergillosis in Chronic Granulomatous Disease
Zeynep Ergenç1
1Department of Pediatric Infectious Diseases and Immunology, Great Ormond Street Hospital for Children, London, United Kingdom;Vaccine Institute and Centre for Neonatal and Pediatric Infection, City St. George’s, University of London, London, United Kingdom
2Department of Pediatric Infectious Diseases and Immunology, Great Ormond Street Hospital for Children, London, United Kingdom;Department of Biosciences, Medical Research Centre for Medical Mycology, University of Exeter, Exeter Faculty of Health and Life Sciences, United Kingdom.
2Department of Pediatric Infectious Diseases and Immunology, Great Ormond Street Hospital for Children, London, United Kingdom;Department of Biosciences, Medical Research Centre for Medical Mycology, University of Exeter, Exeter Faculty of Health and Life Sciences, United Kingdom.
Lokman Hekim Health Sciences 2026; 6(1): 150-158 DOI: 10.14744/lhhs.2025.80707
Abstract
Patients with Chronic Granulomatous Disease (CGD) face the highest lifelong risk of invasive aspergillosis (IA). Effective management of IA in this population requires meticulous care and a well-coordinated, multidisciplinary approach. This includes primary antifungal prophylaxis, timely evaluation and treatment of suspected IA, and the use of diagnostic methods to make a causative diagnosis. In this review, we aim to assess recent advancements in the diagnosis and treatment of IA in patients with CGD.
Keywords: Aspergillus; Chronic granulomatous disease; Infections; Mycology
